Tenderwize
Wróć do wyszukiwania

Non-exclusive rebate agreement for interferon beta-1a injection

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Apr 30, 2028 · 612 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Interferon beta-1a zur subkutanen Injektion (ATC-Code nach WHO: L03AB07)

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice says participation documents are to be submitted via the DTVP communication function, while also stating tha...

Eligibility is limited to pharmaceutical companies under Section 4(18) AMG for the offered product, and Russia-sanction...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclusion of non-exclusive rebate agreements under Section 130a(8) SGB V for pharmaceutical products with active substance interferon beta-1a for subcutaneous injection.
  • Open-house participation model with no individual negotiations and no supply exclusivity.
Pokaż pełne podsumowanie

Open-house framework-style supply arrangement for non-exclusive pharmaceutical rebate agreements for interferon beta-1a for subcutaneous injection (CPV 33600000) led by AOK PLUS. The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. Submission is electronic via DTVP communication functions, but the notice says the portal’s bidding tool is not used for submission in this open-house process. The contract runs until 30 April 2028 at the latest; no contract value is stated and minimum purchase volumes are not guaranteed.

Ryzyka

The notice says participation documents are to be submitted via the DTVP communication function, while also stating tha...

Eligibility is limited to pharmaceutical companies under Section 4(18) AMG for the offered product, and Russia-sanction...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the offered medicinal product.
  • The company or its participating entity must not have a Russia-related link within the meaning of Article 5k of Regulation (EU) No 833/2014 as amended.

Eligibility

  • The self-declaration on the absence of exclusion grounds must be completed and submitted with the participation documents.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive rebate agreement for interferon beta-1a injection

Single lot covering the conclusion of non-exclusive pharmaceutical rebate agreements for medicines containing interferon beta-1a for subcutaneous injection. The lot is an open-house model, so any interested eligible pharmaceutical company may participate during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase quantities are stated. Place of performance is Dresden, Germany.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Apr 2026 - Apr 2028

Kategoria

Pharmaceutical products

Termin

Deadline Apr 30, 2028

Szczegóły zamówienia

Data publikacji
04 Mar 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
155288-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3